A 2-year multicentre, open-label, randomized, controlled study of growth hormone (Genotropin®) treatment in very young children born small for gestational age: Early Growth and Neurodevelopment (EGN) Study

Summary Objective In Europe, growth hormone (GH) treatment for children born small for gestational age (SGA) can only be initiated after 4 years of age. However, younger age at treatment initiation is a predictor of favourable response. To assess the effect of GH treatment on early growth and cognit...

Full description

Saved in:
Bibliographic Details
Published in:Clinical endocrinology (Oxford) 2016-03, Vol.84 (3), p.353-360
Main Authors: De Schepper, Jean, Vanderfaeillie, Johan, Mullis, Primus-E., Rooman, Raoul, Robertson, Anna, Dilleen, Maria, Gomez, Roy, Wollmann, Hartmut A.
Format: Article
Language:English
Subjects:
Adenoids - pathology
Body Height - drug effects
Child Development - drug effects
Child, Preschool
Female
Human Growth Hormone - administration & dosage
Human Growth Hormone - adverse effects
Human Growth Hormone - therapeutic use
Humans
Hypertrophy - chemically induced
Infant
Infant, Newborn
Infant, Small for Gestational Age
Injections, Subcutaneous
Male
Psychomotor Performance - drug effects
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Objective In Europe, growth hormone (GH) treatment for children born small for gestational age (SGA) can only be initiated after 4 years of age. However, younger age at treatment initiation is a predictor of favourable response. To assess the effect of GH treatment on early growth and cognitive functioning in very young (
ISSN:0300-0664
1365-2265
DOI:10.1111/cen.12968